Quince Therapeutics, Inc. (QNCX) OrphAI Therapeutics Inc - M&A Call - Slideshow
Quince Therapeutics, Inc. (QNCX) M&A Call Prepared Remarks Transcript
Quince Therapeutics Announces Acquisition Of Orphai Therapeutics In Stock-For-Stock Deal; Quince Enters Concurrent Private Placement Agreement To Raise Up To $187M
Quince Therapeutics Reports Phase 2a Data For LAM-001 In Pulmonary Hypertension-Associated ILD, Demonstrated Clinically Meaningful Improvement In Multiple Assessments Of Lung Function, Including Improvement In 6MWD Of 67.4 Meters And PVR Reduction Of 33.9% At 24 Weeks; Phase 2b Trial In PH-ILD To Initiate In Mid-2026, With Topline Data Anticipated In Q1 2028
Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending
Quince Therapeutics shares are trading higher after the company announced a settlement of its outstanding obligations under a loan from the European Investment Bank for a payment of $5.5 million.
Quince Therapeutics Settles $5.5M Loan Under Its Obligations From European Investment Bank
BC-Most Active Stocks
What Does the Market Think About Quince Therapeutics Inc?
What Sparked Quince Therapeutics (QNCX) Stock To Rise 53% After Hours
Quince Therapeutics Stock Plunges As Filing Shows Reverse Merger Plans, Bankruptcy Risks
On Wednesday, there are stocks with unusual volume. Let's take a look.
Quince Therapeutics Stock Extends Rally On Strategic Review
Quince Therapeutics, Spotify, S&P Global, Intel And Datadog: Why These 5 Stocks Are On Investors' Radars Today
Quince Therapeutics shares are trading higher after the company announced it is exploring strategic alternatives.
Quince Therapeutics Stock Explodes 300% On Strategic Review
Why Is Quince Therapeutics Stock Soaring Tuesday?
Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives
Quince Therapeutics To Explore Strategic Alternatives, Appoints LifeSci Capital As Financial Adviser
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.
